MMV_award_image

Medicines for Malaria Venture (MMV) award of the year

Medicines for Malaria Venture (MMV) award of the year

On 10 October 2017, Dr. Jetsumon Sattabongkot Prachumsri from MVRU, Mahidol University, Thailand together with Prof. Dennis Kyle, University of South Florida, Prof. Elizabeth Winzeler, University of California received MMV’s Project of the Year 2016. The award recognizes their groundbreaking research working on liver stage P. vivax malaria.

The MMV Project of the Year award is an internal MMV award, established in 2001 to recognize the most exciting drug discovery and development projects in the MMV portfolio and applauds the scientific partners involved. The Project of the Year is selected by MMV’s independent Expert Scientific Advisory Committee at the end of each year.(https://www.mmv.org/research-development/project-year-award)

The awarded studies are different platforms of in vitro system helping to understand complex biology of P. vivax liver stage. This provides new assay platforms for screening and identifying novel drugs that could protect and prevent relapse from the dormant liver stages of P. vivax for the first time.

Ivermectin_for_malaria_elimination_image

Ivermectin for malaria elimination

Ivermectin for malaria elimination

Current interventions such as long-lasting insecticide-treated bed nets (LLINs), indoor residual spraying with insecticides (IRS) and malaria diagnosis and treatment have succeeded and greatly reduce global malaria burden. However, to create a world in which no one dies of malaria, novel and innovative tools are needed due to the emergence of current drug treatment and insecticide resistances.

In early 2017 MVRU has been funded to study the use of Ivermectin for malaria elimination in Thailand. This is a 4-year study funded by Congressional Directed Military Research Program, US Department of Defense. As a part of “Ivermectin Research for Malaria Elimination Network” which was formed after the annual meeting of the American Society of Tropical Medicine and Hygiene (ASTMH) since 2014, this is the first ivermectin study that is performed in malaria endemic area in Asia.

Ivermectin kills a variety of parasites and insects, including the Anopheline (vectors of malaria parasites). Researches showed ivermectin mass drug administration to humans could be toxic to blood-feeding mosquitoes and Plasmodium parasites. Ivermectin addition to current interventions, LLINs and IRS, is becoming a stronger malaria elimination tool.